Abstract: Systems, methods, and devices providing for the robotic installation of vehicle electrical systems are described. A vehicle wiring harness includes first and second cables, a robotic gripping arm, and at least two pairs of stiffeners coupled to the cables to define folding points and corresponding segments that enable robotic folding and unfolding of the wiring harness. In other examples, a wiring harness is coupled to a plurality of electrical connectors carried by a carrier plate of an electrical control unit connection system (ECU), which is installed by robotically mating the plurality of electrical connectors carried by the carrier plate.

Abstract: A module builder includes a wrap floor system including a wrap floor belt wrapped around a front belt sheave and a first drive system coupled to the wrap floor system. The first drive system includes a main drive belt coupled to a rear belt sheave and the front belt sheave, wherein in an engagement mode of operation the main drive belt is tensioned to rotate the rear belt sheave, and in a disengagement mode of operation the main drive belt loses tension to cease rotation of the rear belt sheave. The builder includes a second drive system coupled to a baler belt to drive the baler belt into a module forming chamber. The first drive system further includes one or more of a rear lower gate roller, friction wheel, wrap box roller, electric clutch, or motor to engage and drive the main drive belt.

Abstract: A connector assembly includes a connector housing. The connector housing includes a first side having a first opening. The first opening includes a first planar surface within the connector housing. The connector housing includes a second side having a second opening. The connector assembly includes a terminal with an attachment portion and a conductive member. The conductive member includes a tanged portion. The attachment portion includes a socket opening accessible through the second opening of the connector housing. The connector assembly includes a stuffer insertable into the first opening of the connector housing. The tanged portion of the terminal is engageable with the stuffer to urge the conductive member toward the first planar surface.

Abstract: Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.

Abstract: Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.

Abstract: Biomarkers are described for predicting the efficacy, risk of relapse, risk of an immune related adverse event (irAE), or combination thereof for a CTLA-4 blockade treatment, such as ipilimumab, in a subject with melanoma. Biomarkers are also described for predicting the efficacy and clinical benefit for a PD-1 blockade treatment, such as a PD-1 blocking antibody, in a subject with melanoma.

Abstract: Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.

Abstract: Biomarkers are described for predicting the efficacy, risk of relapse, risk of an immune related adverse event (irAE), or combination thereof for a CTLA-4 blockade treatment, such as ipilimumab, in a subject with melanoma. Biomarkers are also described for predicting the efficacy and clinical benefit for a PD-1 blockade treatment, such as a PD-1 blocking antibody, in a subject with melanoma.

Abstract: Biomarkers are described for predicting the efficacy, risk of relapse, risk of an immune related adverse event (irAE), or combination thereof for a CTLA-4 blockade treatment, such as ipilimumab, in a subject with melanoma. Biomarkers are also described for predicting the efficacy and clinical benefit for a PD-1 blockade treatment, such as a PD-1 blocking antibody, in a subject with melanoma.

Abstract: Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.

Abstract: Biomarkers are described for predicting the efficacy, risk of relapse, risk of an immune related adverse event (irAE), or combination thereof for a CTLA-4 blockade treatment, such as ipilimumab, in a subject with melanoma. Biomarkers are also described for predicting the efficacy and clinical benefit for a PD-1 blockade treatment, such as a PD-1 blocking antibody, in a subject with melanoma.

Abstract: A standby power system for an appliance having a power input coupled to a main power source includes a power enabling device coupled between the main power source and power input of the appliance, a standby power state sensing device coupled to the power enabling device, and a power restore device coupled to the power enabling device.

Abstract: An energy consuming device comprises a power consuming feature/function and a controller operatively connected to the power consuming feature/function. The controller is configured to operate the device including the power consuming feature/function in one of a plurality of operating modes, including at least a normal operating mode during an associated off-peak demand period of an associated energy supplying utility and an energy savings mode during an associated peak demand period of the associated energy supplying utility. The controller is configured to provide a user a grace period during the associated peak demand period to allow the user to change the operating mode of the power consuming feature/function from the energy savings mode to another operating mode including the normal operating mode thereby allowing additional use of the power consuming feature/function during the associated peak demand period.

Abstract: An energy consuming device comprises a power consuming feature/function and a controller operatively connected to the power consuming feature/function. The controller is configured to operate the device including the power consuming feature/function in one of a plurality of operating modes, including at least a normal operating mode during an associated off-peak demand period of an associated energy supplying utility and an energy savings mode during an associated peak demand period of the associated energy supplying utility. The controller is configured to provide a user a grace period during the associated peak demand period to allow the user to change the operating mode of the power consuming feature/function from the energy savings mode to another operating mode including the normal operating mode thereby allowing additional use of the power consuming feature/function during the associated peak demand period.

Abstract: A standby power system for an appliance having a power input coupled to a main power source includes a power enabling device coupled between the main power source and power input of the appliance, a standby power state sensing device coupled to the power enabling device, and a power restore device coupled to the power enabling device.

Abstract: A cooking appliance comprises one or more power consuming features/functions including at least one of a cooking cavity having a heating element and a cooking surface having a surface heating element. A controller is configured to receive and process a signal indicative of current state of an associated energy supplying utility. The controller operates the cooking appliance in one of a plurality of operating modes, including at least a normal operating mode and an energy savings mode, in response to the received signal. The controller is configured to at least one of selectively delay, adjust and disable at least one of the one or more power consuming features/functions to reduce power consumption of the cooking appliance in the energy savings mode.

Abstract: A surgical instrument includes a handle assembly, a flexible conduit, and at least one control member axially movable in the flexible conduit. The handle assembly includes a body member configured to be coupled to the flexible conduit. An actuator is movable on the body member. The actuator includes at least one projection member. The assembly further includes a reinforcement tube having an interior passage sized to accommodate the control member. The reinforcement tube includes a least one bend configured to engage the at least one projection member such that movement of the actuator with respect to the body member causes movement of the reinforcement tube. Methods of manufacturing the handle assembly are also disclosed.

Abstract: A surgical instrument includes a handle assembly, a flexible conduit, and at least one control member axially movable in the flexible conduit. The handle assembly includes a body member configured to be coupled to the flexible conduit. An actuator is movable on the body member. The actuator includes at least one projection member. The assembly further includes a reinforcement tube having an interior passage sized to accommodate the control member. The reinforcement tube includes a least one bend configured to engage the at least one projection member such that movement of the actuator with respect to the body member causes movement of the reinforcement tube. Methods of manufacturing the handle assembly are also disclosed.